Breast cancer genome heterogeneity: a challenge to personalised medicine?
暂无分享,去创建一个
Charles Swanton | P. Futreal | C. Swanton | R. Burrell | P Andrew Futreal | Rebecca A Burrell | Charles Swanton
[1] A. Ashworth,et al. DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1 , 2010, Cancer cell.
[2] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[3] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[4] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[5] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[6] Nicholas D. Socci,et al. Mad2-induced chromosome instability leads to lung tumor relapse after oncogene withdrawal , 2010, Nature.
[7] J. Troge,et al. Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.
[8] A. Børresen-Dale,et al. COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.
[9] Maitreya J. Dunham,et al. Effects of Aneuploidy on Cellular Physiology and Cell Division in Haploid Yeast , 2007, Science.
[10] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[11] Luca Toschi,et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.
[12] R. Houlston,et al. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis , 2008, Gut.
[13] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[14] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[15] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[16] K. A. Gelmon. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .